Please login to the form below

Not currently logged in
Email:
Password:

FDA warns Pfizer over Geodon trials

The FDA issues warning letter claiming Pfizer has failed to correct problems with its testing procedures

The US Food and Drug Administration (FDA) posted a warning letter on its website on April 20 claiming "significant violations" were discovered during an inspection of a Pfizer clinical trial site between May 4 and June 3, 2009. 

The letter, dated April 9, did not mention the name of the medicine and the study, but Pfizer spokeswoman, Kristen Neese, has confirmed it related to the use of Geodon in children with bipolar disorder. Geodon is approved for the treatment of schizophrenia and bipolar disorder in adults, but the company is seeking further approval to use the product in paediatric patients ages 10 to 17. 

In 2006, 26 patients in a company trial of the psychiatric drug received overdoses and, despite Pfizer retraining the physicians, three additional overdoses were documented in 2007.

The July 2009 inspection, which prompted this new warning, however found that Pfizer was still not following its own guidelines for conducting the study safely and was not alerting clinical investigators to new dosing problems as they occur.

The letter demands that, within 15 days, Pfizer notify the FDA in writing of the actions it has taken (including corrective action plans and standard operating procedures) to prevent similar violations in the future. It warns that failure to explain the violations noted above adequately and promptly may result in regulatory action.

According to Neese: "Pfizer has communicated with the FDA about our conduct of clinical trials and, over the next two weeks, will provide an outline of new and existing processes for preventing similar issues with Pfizer clinical trials."

21st April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics